Portal de Periódicos da CAPES

Rendimiento diagnóstico del marcador tumoral CA 19-9 en la diferenciación entre patología bilio-pancreática benigna y maligna

2013; Elsevier BV; Volume: 65; Issue: 4 Linguagem: Inglês

10.4067/s0718-40262013000400004

0718-4026

Jaime Jans B., María J Talma R, Mario Almonacid R, Javier Cruz M., Mauricio Cáceres P, Carla Rosenfeld M, Gladys Jara O,

Neuroendocrine Tumor Research Advances

Accuracy of the tumor marker CA 19-9 in the differentiation of benign and malignant bilio-pancreatic diseasesIntroduction: CA 19-9 has been identified as a derivative of sialic Lewis blood group A and is expressed in 95% of the population.Several studies have documented an overproduction of CA 19-9 in malignant pancreatic and biliary tree diseases.The objective of this study is to determine the accuracy of the tumor marker CA 19-9 differentiating benign and malignant bilio-pancreatic diseases.Material and Methods: Diagnostic test study.We reviewed the records of all patients with malignant bilio-pancreatic diseases and benign biliary calculous diseases evaluated in Hospital Base Osorno between August 2007 and December 2011, with CA 19-9 as part of their study.Results: 71 patients met the inclusion criteria, 17 men and 54 women, with a mean age of 60.7 ± 15.3 years old.Twenty nine (40.8%) cases were benign and 42 (59.2%)cases malignant.For a cutoff level of 37 U/ml the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) to differentiate benign from malignant disease was 81%, 72.4%, 81% and 72.4%, respectively.For a cut off level of 130 U/ml specificity and PPV increased to 96.6% and 96.4%, respectively.Conclusions: The use of CA 19-9 is useful in the diagnosis of patients with suspected bilio-pancreatic malignant disease.The optimization of the normal published value can help to improve accuracy.